Somatropin - Dong-A ST

Drug Profile

Somatropin - Dong-A ST

Alternative Names: DA-3002; Growtropin; Growtropin II; Growtropin-AQ; hGH - Dong-A ST; Human growth hormone - Dong-A ST

Latest Information Update: 19 May 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature

Most Recent Events

  • 01 Feb 2016 Dong-A Pharmaceutical initiates a phase III trial for Short stature (In children, In adolescents; associated with small for gestational age at birth) in South Korea (Parenteral, Injection) (NCT02770157)
  • 16 Jul 2013 Biomarkers information updated
  • 28 Feb 2013 Dong-A Pharmaceutical initiates enrolment in a phase III trial for Short stature in children (associated with Turner's syndrome) in South Korea (NCT01813630)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top